Saltar al contenido principal
Elsevier

Rapid Acting Antidepressants

  • 1 Edición, Volumen 89 - 26 de junio de 2020
  • Última edición
  • Editores: Ronald S. Duman, John H. Krystal
  • Idioma: Inglés

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field.… Leer más

Descripción

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field.

Puntos claves

  • Includes the authority and expertise of leading contributors in pharmacology
  • Presents the latest release in the Advances in Pharmacology series

De interès para

Investigators in neuroscience, pharmacology, neurology, psychiatry, medicine

Índice

Part I – Neurobiology of ketamine effects

    1. Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission

Allie J. Widman and Lori L. McMahon

  • Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition

    •

    Bernhard Luscher, Mengyang Feng and Sarah J. Jefferson

  • The role of eEF2 kinase in the rapid antidepressant actions of ketamine

    •

    Kanzo Suzuki and Lisa M. Monteggia

    Part II – The rapid therapeutic effects of ketamine

  • Clinical overview of NMDA-R antagonists and clinical practice

    •

    Pasha A. Davoudian and Samuel T. Wilkinson

  • Ketamine for depression clinical issues

    •

    Syed Z. Iqbal and Sanjay J. Mathew

  • Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence

    • Lynnette A. Averill, Samar Fouda, James W. Murrough and Chadi G. Abdallah

  • Neurobiological biomarkers of response to ketamine

    •

    Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus and Carlos A. Zarate Jr

  • Relapse prevention in treatment resistant major depressive disorder with rapid-acting antidepressants

    •

    Jaskaran B. Singh, Maggie Fedgchin, Ella J. Daly and Wayne C. Drevets

  • The emergence of ketamine as a novel treatment for posttraumatic stress disorder

    •

    Adriana Feder, Sarah B. Rutter, Daniela Schille and Dennis S. Charney

    Part III – Novel rapid-acting antidepressant mechanisms related to ketamine

  • mGlu2/3 receptor as a novel target for rapid acting antidepressants

    •

    Shigeyuki Chaki

  • Involvement of muscarinic receptor mechanisms in antidepressant drug action

    •

    Jeffrey M. Witkin, Jodi L. Smith, Lalit K. Golani, Emily A. Brooks and Anna E. Martin

  • The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions

    •

    Wayne C. Drevets, Anindya Bhattacharya and Maura L. Furey

    Detalles del producto

    • Edición: 1
    • Última edición
    • Volumen: 89
    • Publicado: 29 de junio de 2020
    • Idioma: Inglés

    Sobre los editores

    RD

    Ronald S. Duman

    Ronald Duman is at Yale University School of Medicine, CT, USA
    Afiliaciones y experiencia
    Yale University School of Medicine, CT, USA

    JK

    John H. Krystal

    John Krystal is at Yale University, CT, USA
    Afiliaciones y experiencia
    Yale University, CT, USA

    Ver libro en ScienceDirect

    Lee Rapid Acting Antidepressants en ScienceDirect